Leukemia News

Although potentially curative for many hematologic malignancies, hematopoietic stem cell transplantation historically has been associated with substantial morbidity and mortality.

Although chimeric antigen receptor T-cell therapies are being administered more frequently, they are still available only at a limited number of specialized centers.

ASH awarded funding to 19 early-career investigators to support resumption of research paused due to the COVID-19 pandemic.

Whole-genome sequencing appeared as accurate as and more efficient than conventional cytogenetic tests for genomic profiling of acute myeloid leukemia and myelodysplastic syndrome, according to data in The New England Journal of Medicine.

The Society for Immunotherapy of Cancer published clinical practice guidelines on the management of toxicities related to the use of immune effector cell therapies, including chimeric antigen receptor T cells.

Nearly one-third of people diagnosed with blood cancers indicated they either are unlikely to get a COVID-19 vaccine or are unsure about doing so, survey results released today by Leukemia & Lymphoma Society showed.

Results of two studies published in JAMA showed the addition of blinatumomab to consolidation chemotherapy improved outcomes for children and young adults with high-risk first relapse of B-cell acute lymphoblastic leukemia.

The Leukemia & Lymphoma Society launched a national patient registry designed to improve understanding of how the novel coronavirus and COVID-19 vaccination affect people with blood cancer.

Eprenetapopt plus azacitidine appeared well-tolerated and yielded high remission rates among patients with TP53-mutated myelodysplastic syndrome and oligoblastic acute myeloid leukemia, according to results of a phase 1b/phase 2 trial.

COVID-19 infections in patients with hematologic malignancies tend to have a much worse prognosis, with mortality rates twice as high as those of patients without hematologic malignancies. These rates are currently up to 34% overall among adults and up to 47% among those aged older than 60 years. Underlying immunosuppression related to the malignancy itself and further potentiated by the therapy likely contributes to high mortality seen among these patients.